Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama.
Naka Kinen Clinic, Naka, Japan.
J Diabetes Investig. 2010 Oct 19;1(5):208-11. doi: 10.1111/j.2040-1124.2010.00046.x.
To investigate the factors contributing to pioglitazone-induced edema, we analyzed sodium excretion and several clinical parameters before and after administration of pioglitazone. We analyzed these parameters before and after 8 weeks of administration of pioglitazone to female subjects with type 2 diabetes. When we evaluated whether a significant correlation was found between salt excretion and blood pressure, six patients showed such correlation and 20 patients did not. After 8 weeks of pioglitazone administration, five patients had developed edema, and, surprisingly, such correlation was not found in all five subjects. Salt excretion after administration of pioglitazone was significantly lower in subjects who developed edema and those who showed the correlation, and the hematocrit was significantly lower after administration in the subjects who showed the correlation, but not in the edema group. Pioglitazone-induced edema would be caused not only by fluid retention, but also by other factors, such as vascular permeability. (J Diabetes Invest, doi: 10.1111/ j.2040-1124.2010.00046.x, 2010).
为了探究吡格列酮导致水肿的原因，我们分析了女性 2 型糖尿病患者在服用吡格列酮前后钠排泄和几个临床参数的变化。我们分析了这些参数在女性 2 型糖尿病患者服用吡格列酮 8 周前后的变化。当我们评估盐排泄和血压之间是否存在显著相关性时，6 例患者存在这种相关性，而 20 例患者不存在。在服用吡格列酮 8 周后，5 例患者出现水肿，而令人惊讶的是，所有 5 例患者均未发现这种相关性。出现水肿和存在相关性的患者在服用吡格列酮后盐排泄量显著降低，且存在相关性的患者在服用后血细胞比容显著降低，但在水肿组患者中则未发现这种变化。吡格列酮引起的水肿不仅是由于液体潴留，还可能与其他因素有关，如血管通透性。（糖尿病研究与临床实践，doi: 10.1111/ j.2040-1124.2010.00046.x，2010）。
Zotero 插件